BIOA Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Bioage Labs's net margin of 10.05%. Bioage Labs's return on equity of -- beat Electromed's return on equity of 15.62%.

Bioage Labs has a consensus price target of --, signalling upside risk potential of 15.15%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 12.86%. Given that Bioage Labs has higher upside potential than Electromed, analysts believe Bioage Labs is more attractive than Electromed.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are --, which are smaller than Electromed quarterly revenues of $14.7M. Bioage Labs's net income of -$13.6M is lower than Electromed's net income of $1.5M. Notably, Bioage Labs's price-to-earnings ratio is -- while Electromed's PE ratio is 40.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 4.57x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to Bioage Labs's net margin of 8.48%. Bioage Labs's return on equity of -- beat Eli Lilly and's return on equity of 66.4%.

Bioage Labs has a consensus price target of --, signalling upside risk potential of 15.15%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 23.91%. Given that Eli Lilly and has higher upside potential than Bioage Labs, analysts believe Eli Lilly and is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.30 per share. Bioage Labs pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bioage Labs quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Bioage Labs's net income of -$13.6M is lower than Eli Lilly and's net income of $970.3M. Notably, Bioage Labs's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 85.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 17.57x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -- compared to Bioage Labs's net margin of -10.5%. Bioage Labs's return on equity of -- beat Myomo's return on equity of -84.04%.

Bioage Labs has a consensus price target of --, signalling upside risk potential of 15.15%. On the other hand Myomo has an analysts' consensus of $7.04 which suggests that it could grow by 19.42%. Given that Myomo has higher upside potential than Bioage Labs, analysts believe Myomo is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Myomo has a beta of 1.709, suggesting its more volatile than the S&P 500 by 70.858%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are --, which are smaller than Myomo quarterly revenues of $9.2M. Bioage Labs's net income of -$13.6M is lower than Myomo's net income of -$966.4K. Notably, Bioage Labs's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 9.38x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Bioage Labs's net margin of -17.98%. Bioage Labs's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.98%.

Bioage Labs has a consensus price target of --, signalling upside risk potential of 15.15%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 418.19%. Given that Xtant Medical Holdings has higher upside potential than Bioage Labs, analysts believe Xtant Medical Holdings is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Bioage Labs's net income of -$13.6M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Bioage Labs's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 0.51x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.